Sydney to Hobart yacht race: LawConnect wins back-to-back line honours in event marred by two deaths
Trump asks US supreme court to pause ban-or-divest law for TikTok
Albania bans TikTok for a year after fatal stabbing of teenager last month
Trump nominates Miami-Dade official as Panama ambassador amid canal row
ECB faces tough task after flip in fortunes for eurozone economies
Market value drops by 6% on concerns that new lung cancer drug may not be as successful as hoped
Nearly £10bn has been wiped off the stock market value of AstraZeneca over concerns that a new lung cancer drug may not be as successful as had been hoped.
Shares in the Anglo-Swedish pharmaceutical company fell by as much as 6% on Monday morning after it published the first results from its phase 3 trial for datopotamab deruxtecan, making it the biggest faller among FTSE 100 companies.
More Stories
How I beat overwhelm: I deleted my email app – and my sleep suddenly improved
OpenAI lays out plan to shift to for-profit corporate structure
Sound advice from John Cage | Letters